IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice.
The toxicity and antitumor efficacy of simian IL-15 was compared with human IL-2 in the context of syngeneic BMT. Groups of mice receiving or not receiving anti-CD3 activated splenocytes, termed "T-activated killer" (T-AK) cells, were treated between days 7 and 12 with escalating doses of IL-2 or IL-15 given twice daily. Recipients of IL-2+T-AK or IL-15+T-AK had significantly higher survival rates than saline+T-AK. Tissues from IL-2+T-AK, but not IL-15+Y-AK, treated mice revealed the presence of perivascular infiltrates in the lung and liver consisting of CD8+ T cells and Mac-1+ cells. Our findings demonstrate that IL-15 can be used effectively to stimulate antitumor responses post-BMT and may be associated with less toxicity than IL-2.
Katsanis
E
E
Department of Pediatrics and Medicine, University of Minnesota, Minneapolis 55455, USA.
Xu
Z
Z
Panoskaltsis-Mortari
A
A
Weisdorf
D J
DJ
Widmer
M B
MB
Blazar
B R
BR
D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016219:Immunotherapy, Adoptive; D019409:Interleukin-15 / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000187:drug effects / Q000637:transplantation; D016393:Lymphoma, B-Cell / Q000628:therapy*; D016853:Muromonab-CD3 / Q000494:pharmacology
D007155:Immunologic Factors; D019409:Interleukin-15; D007376:Interleukin-2; D016853:Muromonab-CD3